Drug Profile
Research programme: erythropoietin gene expression inducers - Aventis/OSI
Latest Information Update: 30 Oct 1998
Price :
$50
*
At a glance
- Originator Aventis; OSI Pharmaceuticals
- Class Small molecules
- Mechanism of Action Erythropoiesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Anaemia
Most Recent Events
- 30 Oct 1998 Discontinued-Preclinical for Anaemia in USA (PO)
- 28 May 1998 Preclinical development for Anaemia in USA (PO)